ADAP

0.595

1.43% 0.0084

Handel nachbörslich: .64 0.045 +7.56%

Adaptimmune Therapeutics Plc Adr (ADAP)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.5866

Offen:

$0.6

24-Stunden-Volumen:

1.79M

Relative Volume:

1.30

Marktkapitalisierung:

$158.36M

Einnahmen:

$175.04M

Nettoeinkommen (Verlust:

$-44.52M

KGV:

-1.1146

EPS:

-0.5338

Netto-Cashflow:

$-56.05M

1W Leistung:

-27.80%

1M Leistung:

-29.39%

6M Leistung:

-46.40%

1J Leistung:

+24.22%

1-Tages-Spanne:

$0.58

$0.6393

1-Wochen-Bereich:

$0.58

$0.8334

52-Wochen-Spanne:

$0.42

$2.05

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Firmenname

Adaptimmune Therapeutics Plc Adr

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

44 1235 430000

Adresse

60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE

Mitarbeiter

449

Twitter

@Adaptimmune

Nächster Verdiensttermin

2024-12-13

Neueste SEC-Einreichungen

ADAP's Discussions on Twitter

Vergleichen Sie ADAP mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ADAP	0.595	158.36M	175.04M	-44.52M	-56.05M	-0.5338
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-03-24	Eingeleitet	Bryan Garnier	Buy
2023-01-03	Hochstufung	Guggenheim	Neutral → Buy
2022-11-09	Hochstufung	Mizuho	Neutral → Buy
2021-05-28	Eingeleitet	Barclays	Underweight
2020-04-22	Eingeleitet	Mizuho	Neutral
2019-08-02	Herabstufung	Guggenheim	Buy → Neutral
2019-05-31	Eingeleitet	ROTH Capital	Buy
2019-05-30	Fortgesetzt	Citigroup	Buy
2019-05-07	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2017-03-17	Eingeleitet	Wells Fargo	Market Perform
2016-10-24	Herabstufung	BofA/Merrill	Neutral → Underperform
2016-09-30	Eingeleitet	Raymond James	Outperform
2016-02-25	Eingeleitet	Citigroup	Buy
2015-06-01	Eingeleitet	BofA/Merrill	Neutral
2015-06-01	Eingeleitet	Guggenheim	Buy
2015-06-01	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten

08:32 AM

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

08:32 AM

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

08:32 AM

Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024

Nov 01, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024

Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024

Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024

Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024

Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024

Oct 07, 2024